Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS:  Peter Read More

2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. AUTHORS: Peter Read More

2024-03-25T09:19:31-07:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Read More

2024-03-25T10:51:59-07:00August 15th, 2012|BluePrint, Evidence, Other, Validation|
Go to Top